Persistence of chemotherapy-induced DNA damage has been observed in wild-type p53 glioblastoma cells [92] as well as p53 deleted or mutant p53 ovarian cells [6] treated with the first-generation MDM2 antagonist Nutlin3a and this correlated with increases in MDM2 expression and cell death. This evidence concerns the gene TP53 and glioblastoma.